CG Oncology Inc (CGON)
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec for patients with bladder cancer in the United States. Its lead candidate, cretostimogene, is an investigational oncolytic immunotherapy being evaluated across several clinical programs, including phase 2 studies in high-risk non-muscle invasive bladder cancer after BCG failure and multiple phase 3 trials in BCG-unresponsive and papillary-only disease settings. The pipeline also includes phase 3 development in intermediate-risk NMIBC after TURBT and phase 2 work in high-risk NMIBC covering both BCG-exposed and BCG-naive patients. Formerly known as Cold Genesys, Inc., the company adopted the CG Oncology name in June 2020. It was founded in 2010 and is headquartered in Irvine, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CGON
|
$58.51
|
-17.4% Downside
|
Fair
|
$90.29
|
27.5% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 7, 2026
|
-33.5x
|
5.7x
|
1,232.0x
|
6.191 B
|
5.179 B
|
0.1%
|
74.6%
|
85.4
|
—
|
85.9%
|
